Results 71 to 80 of about 675,123 (288)

SOMATOSTATIN RECEPTORS AS POTENTIALTHERAPEUTIC TARGETS IN THE TREATMENT OF ADVANCED ADRENOCORTICAL CANCER. A CASE REPORT

Сибирский онкологический журнал, 2018
Background. Adrenocortical cancer (ACC) is a rare malignancy of the adrenal cortex. Therapeutic options for advanced ACC are limited. It is necessary to study new and more effective drug combinations and tumor biological targets. The purpose of the study
A. A. Kolomeytseva, V. V. Delektorskaya, N. F. Orel, G. S. Emelianova, V. Y. Bokhian, A. A. Fedenko   +5 more
doaj   +1 more source

Targeted paclitaxel‐octreotide conjugates inhibited the growth of paclitaxel‐resistant human non‐small cell lung cancer A549 cells in vitro

Thoracic Cancer, 2021
The application of chemotherapy in non‐small cell lung cancer (NSCLC) is limited by the toxicity to normal cells and the development of multi‐drug resistance.
Yanguo Liu, Handai Xia, Yawei Wang, Wenfei Han, Jing Qin, Wenjuan Gao, Xun Qu, Xiuwen Wang   +7 more
doaj   +1 more source

Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. [PDF]

, 2014
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome associated with the development of many endocrine tumors, involving mainly pituitary, parathyroids, pancreas, although a proliferative state interests all neuroendocrine system.
Camera, L, Carratù, A, Colao, A, de Luca di Roseto, C, Del Prete, M, Di Somma, C, Faggiano, A., Marciello, F, Marotta, V, Ramundo, V   +9 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells

Frontiers in Pharmacology, 2019
Prostate cancer (PC) is one of the most frequently diagnosed cancers and a leading cause of cancer-related deaths in Western society. Current PC therapies prevalently target the functions of androgen receptor (AR) and may only be effective within short ...
Valentina Rossi, Erika Di Zazzo, Giovanni Galasso, Caterina De Rosa, Ciro Abbondanza, Antonio A. Sinisi, Lucia Altucci, Antimo Migliaccio, Gabriella Castoria   +8 more
doaj   +1 more source

Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism [PDF]

, 2017
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when ...
Abraham, Berg, Bruns, Church, Colao, Colao, Combes, Cozzi, Dowling, Dunning, Feelders, Freda, Gadelha, Henry, Hofland, Hubina, Hussaini, Jaffe, Katznelson, Kurosaki, Lamb, Laron, Ma, Meij, Meij, Myers, Niessen, Niessen, Niessen, Patel, Petersenn, Peterson, Reubi, Reusch, Reusch, Sathyapalan, Schaefer, Scudder, Shanik, Slingerland, Slingerland, Theodoropoulou, Tyson, Zambre   +43 more
core   +3 more sources

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma

International Journal of Endocrinology, 2018
The development of somatostatin analogs for the treatment of pituitary Cushing’s disease has been based on somatostatin receptor expression analyses of small cohorts of pituitary adenomas.
Felix Behling, Jürgen Honegger, Marco Skardelly, Irina Gepfner-Tuma, Ghazaleh Tabatabai, Marcos Tatagiba, Jens Schittenhelm   +6 more
doaj   +1 more source

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders

Molecules, 2020
Hematological and oncological disorders represent leading causes of childhood mortality. Neuropeptide somatostatin (SST) has been previously demonstrated in various pediatric tumors, but limited information exists on the expression and characteristics of
Kristof Harda, Zsuzsanna Szabo, Eva Juhasz, Balazs Dezso, Csongor Kiss, Andrew V. Schally, Gabor Halmos   +6 more
doaj   +1 more source

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours [PDF]

, 2003
Five somatostatin receptor (sst) subtype genes, sst(1), sst(2), sst(3), sst(4) and sst(5), have been cloned and characterised. The five sst subtypes all bind natural somatostatin-14 and somatostatin-28 with high affinity.
Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der   +3 more
core   +2 more sources